2024-09-14
September 14, 2024, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") self-developed product Procaterol Hydrochloride Inhalation Solution (trade name:倍舒捷®)has been successfully approved by the Chinese CDE, and Beimei Pharmaceutical is the MAH of this product.
✦
•
✦
✦
左右滑动，查看更多
✦
Procaterol Hydrochloride Inhalation Solution is mainly used to relieve various symptoms based on airflow restriction in the following diseases: bronchial asthma, chronic bronchitis, emphysema.
Procaterol Hydrochloride is a β2 adrenergic receptor agonist, which is highly selective to bronchial β2 receptors, and has the characteristics of rapid onset and long-lasting efficacy.
Inhalation solution formulation is beneficial for delivering drugs quickly and accurately to the bronchus and lungs, which can quickly exert the antispasmodic effect of drugs and relieve patients' respiratory distress symptoms.
Beimei Pharmaceutical has been approved for two specifications, 0.3ml:30 μg and 0.5ml:50 μg, both have indications for children and provide more suitable dosage choice for patients of different ages.
About Beimei Pharma
Shenzhen Beimei Pharmaceutical Co., Ltd. ("Beimei Pharma") focuses on the field of pediatric prescription medicines, integrating full-spectrum capabilities of R&D, manufacture, commercialization and global cooperation, driven by the core strategy of self-development and global collaboration via in-licensing, asset purchase acquisition etc. Synergizing with the manufacture base in Liangyungang to fulfil sufficient production and global supply of diversified special formulations for children's medications, Beimei is aiming to provide pediatric patients with high-quality and full range of drugs.
Beimei Pharma has more than 40 pediatric drug products in portfolio and pipeline, including 5 approved drugs launched in the market, and several innovative drugs with global rights and independent intellectual property rights. The current pipeline covers the therapeutic fields of dermatology, respiratory, gastroenterology, anti-infection, neurology, neonatal, endocrinology, etc.
Beimei Pharma has established long-term partnerships with multiple large international pharmaceutical companies, such as Hetero, Cipla, Deva, Dr. Reddy’s, LTS, MedPharma, Synthon, EMP, NTC, Syrimed, etc.
Beimei Pharma has completed the Angel Round, Round A, Round B/B+ and Round C financing with hundreds of millions of RMB. Beimei Pharma gained recognition from many well-known investment institutions, including Efung Capital and the industrial parties.
For additional information, please visit the website: http://www.beimeiyaoye.com/
